These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 15637733)

  • 21. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
    Andrews JM; Travis SP; Gibson PR; Gasche C
    Aliment Pharmacol Ther; 2009 Mar; 29(5):459-69. PubMed ID: 19077129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
    Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
    Giannini EG; Kane SV; Testa R; Savarino V
    Dig Liver Dis; 2005 Oct; 37(10):723-31. PubMed ID: 16023905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemoprevention of colorectal cancer in inflammatory bowel disease].
    Han SH; Lee J
    Korean J Gastroenterol; 2014 Jan; 63(1):3-10. PubMed ID: 24463282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Will a 5-ASA a day keep the cancer (and dysplasia) away?
    Rubin DT; Lashner BA
    Am J Gastroenterol; 2005 Jun; 100(6):1354-6. PubMed ID: 15929769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemoprevention of colorectal cancer in ulcerative colitis.
    Croog VJ; Ullman TA; Itzkowitz SH
    Int J Colorectal Dis; 2003 Sep; 18(5):392-400. PubMed ID: 12904996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question.
    Margagnoni G; Pagnini C; Menasci F; Festa S; Delle Fave G
    Curr Clin Pharmacol; 2014 Feb; 9(1):84-90. PubMed ID: 24218994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease.
    Mpofu C; Watson AJ; Rhodes JM
    Cochrane Database Syst Rev; 2004; (2):CD000279. PubMed ID: 15106148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate.
    Mouzas IA; Papavassiliou E; Koutroubakis I
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):421-5. PubMed ID: 9789142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Aminosalicylic acid, a specific drug for ulcerative colitis.
    Hauso Ø; Martinsen TC; Waldum H
    Scand J Gastroenterol; 2015 Aug; 50(8):933-41. PubMed ID: 25733192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential Role of Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention for Inflammatory Bowel Disease: An Umbrella Review.
    Newman P; Muscat J
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidized 5-aminosalicylic acid activates Nrf2-HO-1 pathway by covalently binding to Keap1: Implication in anti-inflammatory actions of 5-aminosalicylic acid.
    Kang S; Kim W; Jeong S; Lee Y; Nam J; Lee S; Jung Y
    Free Radic Biol Med; 2017 Jul; 108():715-724. PubMed ID: 28473247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.
    Razik R; Rumman A; Bahreini Z; McGeer A; Nguyen GC
    Am J Gastroenterol; 2016 Aug; 111(8):1141-6. PubMed ID: 27215924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Ehrlich AC; Patel S; Meillier A; Rothstein RD; Friedenberg FK
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):247-255. PubMed ID: 28095263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoprevention of colorectal cancer: feasibility in everyday practice?
    Herszényi L; Farinati F; Miheller P; Tulassay Z
    Eur J Cancer Prev; 2008 Nov; 17(6):502-14. PubMed ID: 18941372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopy/surveillance in inflammatory bowel disease.
    Ahmadi AA; Polyak S
    Surg Clin North Am; 2007 Jun; 87(3):743-62. PubMed ID: 17560423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
    Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
    J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.